ATRX loss was a favorable prognostic factor only in WHO II astrocytoma patients, but in all the glioma patients, it has no statistically significant (Median OS was 28 to 25, p=0.457). The gene discussed is ATRX; the disease is astrocytoma (excluding glioblastoma).